Australia - English - Department of Health (Therapeutic Goods Administration)

leading advance group pty ltd - natural fish oil, quantity: 500 mg (equivalent: docosahexaenoic acid, qty 60 mg; equivalent: eicosapentaenoic acid, qty 90 mg); d-alpha-tocopherol, quantity: 38.5 mg (equivalent: d-alpha-tocopherol, qty 50 iu); ubidecarenone, quantity: 150 mg - capsule, soft - excipient ingredients: soya oil; lemon oil; hydrogenated vegetable oil; glycerol; sunset yellow fcf; lecithin; titanium dioxide; gelatin; yellow beeswax; iron oxide red; purified water; lime oil coldpressed - antioxidant/reduce free radicals formed in the body ; enhance/promote energy levels ; maintain/support cardiovascular system health ; helps reduce occurrence of symptoms of headaches

Australia - English - Department of Health (Therapeutic Goods Administration)

universal pharmaceuticals pty ltd - natural fish oil, quantity: 500 mg; ubidecarenone, quantity: 150 mg; d-alpha-tocopherol, quantity: 100.68 mg - capsule, soft - excipient ingredients: purified water; d-alpha-tocopherol; lecithin; soya oil; glycerol; iron oxide red; gelatin; yellow beeswax; sunset yellow fcf aluminium lake - antioxidant/reduce free radicals formed in the body ; maintain/support energy levels ; helps in the maintenance of healthy blood lipids/blood fats ; maintain/support cardiovascular system health ; maintain/support heart health

Israel - English - Ministry of Health

teva pharmaceutical industries ltd, israel - tocopherol (vit e) (as tocopheryl acetate) - tablets - tocopherol (vit e) (as tocopheryl acetate) 100 mg - tocopherol (vit e) - tocopherol (vit e) - for the prevention and treatment of diseases caused by vitamin e deficiency.

Israel - English - Ministry of Health

teva pharmaceutical industries ltd, israel - tocopherol (vit e) (as tocopheryl acetate) - tablets - tocopherol (vit e) (as tocopheryl acetate) 200 mg - tocopherol (vit e) - tocopherol (vit e) - for the prevention and treatment of diseases caused by vitamin e deficiency.

Israel - English - Ministry of Health

teva pharmaceutical industries ltd, israel - tocopherol (vit e) (as tocopheryl acetate) - tablets - tocopherol (vit e) (as tocopheryl acetate) 200 mg - tocopherol (vit e) - tocopherol (vit e) - for the prevention and treatment of diseases caused by vitamin e deficiency.

Australia - English - Department of Health (Therapeutic Goods Administration)

australian naturalcare products pty ltd - d-alpha-tocopherol, quantity: 335.39 mg - capsule, soft - excipient ingredients: glycerol; hydrogenated vegetable oil; gelatin; soya oil; purified water - antioxidant/reduce free radicals formed in the body ; helps reduce/decrease free radical damage to body cells ; maintain/support general health and wellbeing ; maintain/support cardiovascular system health ; maintain/support healthy cardiovascular system function ; maintain/support heart health ; maintain/support immune system health ; maintain/support healthy immune system function

Australia - English - Department of Health (Therapeutic Goods Administration)

ausway pharmaceutical pty ltd - natural fish oil, quantity: 500 mg (equivalent: eicosapentaenoic acid, qty 90 mg; equivalent: docosahexaenoic acid, qty 60 mg); ubidecarenone, quantity: 150 mg - capsule, soft - excipient ingredients: glycerol; yellow beeswax; iron oxide red; sunset yellow fcf; lecithin; purified water; titanium dioxide; hydrogenated vegetable oil; gelatin; soya oil; d-alpha-tocopherol - antioxidant/reduce free radicals formed in the body ; maintain/support energy production ; maintain/support general health and wellbeing ; maintain/support healthy cardiovascular system function ; maintain/support heart health

United States - English - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u), norethindrone acetate (unii: 9s44lic7oj) (norethindrone - unii:t18f433x4s) - ethinyl estradiol 0.02 mg - norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets are indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. oral contraceptives are highly effective. table i lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. the efficacy of these contraceptive methods, except sterilization, depends upon the reliability with which they are used. correct and consistent use of methods can result in lower failure rates. % of women experiencing an unintended pregnancy in the first year of continuous use method lowest expected * typical † (no contraception)  (85) (85) oral contraceptives  3       combined  0.1 n/a ‡       progestin only  0.5 n/a ‡ diaphragm with spermicidal cream or jelly  6 20 spermicides alone (foam, creams, gels, vaginal suppositories, and vaginal film)  6 26 vaginal sponge       nulliparous  9 20       parous 20 40 implant  0.05 0.05 injection: depot medroxyprogesterone acetate  0.3 0.3 iud       progesterone t  1.5 2.0       copper t 380a  0.6 0.8       lng 20  0.1 0.1 condom without spermicides       female  5 21       male  3 14 cervical cap with spermicidal cream or jelly       nulliparous  9 20       parous  26 40 periodic abstinence (all methods)  1-9 25 withdrawal  4 19 female sterilization  0.5 0.5 male sterilization  0.10 0.15  

United States - English - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u), norethindrone acetate (unii: 9s44lic7oj) (norethindrone - unii:t18f433x4s) - ethinyl estradiol 20 ug - norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets are indicated for use by females of reproductive age to prevent pregnancy [see clinical studies (14)] . the efficacy of norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets in women with a body mass index (bmi) of more than 35 kg/m2 has not been evaluated. do not prescribe norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets to women who are known to have the following conditions: there is little or no increased risk of birth defects in women who inadvertently use cocs during early pregnancy. epidemiologic studies and meta-analyses have not found an increased risk of genital or non-genital birth defects (including cardiac anomalies and limb reduction defects) following exposure to low dose cocs prior to conception or during early pregnancy. the administration of cocs to induce withdrawal bleeding should not be used as a test for pregnancy. cocs should not be used during preg

United States - English - NLM (National Library of Medicine)

stuart products, inc. - alpha-tocopherol, d- (unii: n9pr3490h9) (.alpha.-tocopherol, d- - unii:n9pr3490h9), vitamin a palmitate (unii: 1d1k0n0vvc) (vitamin a - unii:81g40h8b0t), cholecalciferol (unii: 1c6v77qf41) (cholecalciferol - unii:1c6v77qf41) - alpha-tocopherol, d- 500 [iu] in 1 ml - indications: vital e–newborn is a clear, sterile, non-aqueous solution of vitamins e, a and d for use as a supplemental source of vitamin e, vitamin a and vitamin d in newborn calves, lambs and piglets. each ml provides vitamin e in its highest biologically-available form d-alpha tocopherol, the same form found in colostrum and milk. newborns are born deficient in fat-soluble vitamins and depend on colostrum and milk to provide adequate amounts. a reduced intake of these critically important vitamins can result in marginal deficiencies that may not be visible. intramuscular or subcutaneous injections of vital e-newborn  offer an efficient and rapid method to increase the status of vitamins e, a and d in newborns. administration and dosage: intramuscular or subcutaneous adminstration only. suggested dosage: calves (dairy and beef)    at birth                        3-5 ml lambs    at birth                        1-2 ml piglets    at birth                         1/2 ml    at weaning                     1 ml